CytomX Therapeutics Expands Cancer Therapy Partnership With Regeneron; Shares Rise
MT Newswires Live
Jun 03
CytomXTherapeutics (CTMX) said Wednesday it is expanding a licensing agreement with Regeneron Pharmaceuticals (REGN) to develop conditionally activated bispecific cancer treatments.
CytomX said it will receive a $37 million target nomination payment for two newly chosen development programs.
Regeneron holds the right to select up to six more targets, bringing the overall potential milestone value of the broadened agreement to roughly $4 billion, CytomX said.
Shares CytomX were more than 5% higher premarket trading, while Regeneron was down 0.5%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.